EU: EMA to reinstate some activities halted by Brexit


EU: EMA to reinstate some activities halted by Brexit

(Source: RAPS 2019-06-18)

While noting some progress in its Brexit preparations on transferring medicine marketing authorizations from the UK to the EU, the European Medicines Agency (EMA) on Monday announced a series of activities that will ramp up, in addition to the highest priority activities, for the remainder of 2019.

But EMA also reiterated that between 20% and 25% of the agency’s staffers are expected to leave. And in the most recent EMA update, of the agency’s 776 staff members, 464 have relocated to the EMA’s new headquarters in the Netherlands, but 312 are working remotely, mostly from London.

“Due to resource constraints, most activities temporarily suspended at the end of 2018 remain on hold. These include guideline development, most working party meetings, engagement in international activities and the proactive publication of clinical data. A further review by EMA's Management Board will take place in October 2019,” EMA said.

As far as the new activities to be reinstated, EMA said the focus will be on projects aiming to increase the efficiency of EMA’s operations, such as with IT systems supporting medicine evaluations and the digitalization of administrative processes. Key public health priorities, including the availability of medicines and antimicrobial resistance (AMR) will also see renewed work, in addition to the restarting of some of the EU network working groups.

To continue reading this article please go to RAPS

New Article